Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Mylan NV    MYL   NL0011031208

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/12/2017 12/13/2017 12/14/2017 12/15/2017 12/18/2017 Date
39.29(c) 39.53(c) 40.01(c) 40.52(c) 41.89 Last
10 735 600 6 082 461 19 491 982 11 767 734 5 421 626 Volume
-0.51% +0.61% +1.21% +1.27% +3.38% Change
More quotes
Financials ($)
Sales 2017 11 990 M
EBIT 2017 3 405 M
Net income 2017 1 265 M
Debt 2017 13 788 M
Yield 2017 -
Sales 2018 12 746 M
EBIT 2018 3 762 M
Net income 2018 1 967 M
Debt 2018 11 658 M
Yield 2018 -
P/E ratio 2017 17,51
P/E ratio 2018 11,00
EV / Sales2017 2,96x
EV / Sales2018 2,62x
Capitalization 21 730 M
More Financials
Company
Mylan N.V., is a pharmaceutical company which engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products.The company was founded on July 7, 2014 and is headquartered in Hatfield, United Kingdom. 
Sector
Pharmaceuticals
Calendar
02/28Earnings Release
More about the company
Surperformance© ratings of Mylan NV
Trading Rating : Investor Rating :
More Ratings
Latest news on MYLAN NV
12/14 Perrigo lines up bid for Merck's consumer health unit - sources
12/14 MYLAN : Announces the U.S. Patent and Trademark Appeal Board Institutes Inter Pa..
12/11 MYLAN : Teva Dismisses Litigation After Mylan Wins U.S. Court Ruling Related to ..
12/05DJRoche's Breast Cancer Drug Herceptin Faces Biosimilar Competition -Cinco Dias
12/04 MYLAN NV : Today’s Research Reports on Stocks to Watch: Mylan and Nutanix
12/04 MYLAN : and Aspen Announce Launch of Generic Busulfex® Injection
12/01 Tech firms tell patent court to ignore Allergan deal with tribe
12/01 MYLAN : U.S. FDA Approves Mylan and Biocon's Ogivri™, the First Biosimilar..
12/01 MYLAN : FDA Approval of Heparin Sodium Injection Continues to Demonstrate Mylan'..
11/30 MYLAN : European Medicines Agency Accepts Marketing Authorization Applications f..
More news
Sector news : Pharmaceuticals - NEC
06:32p Pfizer announces new $10 billion share buyback, hikes dividend
06:18pDJPFIZER : Raises Dividend 6%, Sets New $10 Billion Buyback Program
03:47p TEVA PHARMACEUTICAL INDUSTRIES : Union says workers at Israeli drugs firm Teva t..
03:47p TEVA PHARMACEUTICAL INDUSTRIES : Union says workers at Israeli drugs firm Teva t..
01:42p GLAXOSMITHKLINE : boosts stake in Saudi Arabia unit
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
12/16 Teva - Aggressive Cuts Provide Relief
12/15 Does Teva Really Have $5 Billion In Debt Payments Due Next Year?
12/15 European advisory group backs Mylan's generic Xagrid
12/14 Challenge of two Lantus patents commences
12/14 YOUR DAILY PHARMA SCOOP : Right Time To Buy Regeneron, Eli Lilly Gives Guidance,..
Chart MYLAN NV
Duration : Period :
Mylan NV Technical Analysis Chart | MYL | NL0011031208 | 4-Traders
Technical analysis trends MYLAN NV
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 43,7 $
Spread / Average Target 7,7%
EPS Revisions
Managers
NameTitle
Heather M. Bresch Chief Executive Officer & Director
Rajiv Malik President & Director
Robert J. Coury Executive Chairman
Kenneth Scott Parks Chief Financial Officer
Wendy Cameron Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
MYLAN NV6.21%21 730
JOHNSON & JOHNSON23.65%382 722
PFIZER14.53%221 738
NOVARTIS13.09%221 731
ROCHE HOLDING LTD.4.94%212 270
MERCK AND COMPANY-4.47%153 386